Amicus Therapeutics, Inc. (FOLD)
NASDAQ: FOLD · Real-Time Price · USD
6.83
+0.13 (1.87%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Amicus Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Amicus Therapeutics stock have an average target of 17, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 149.08% from the current stock price of 6.83.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 20, 2025.
Analyst Ratings
The average analyst rating for Amicus Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 2 | 2 | 3 | 3 | 3 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +149.08% | Feb 20, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +207.69% | Jan 15, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 13, 2025 |
| Morgan Stanley | Morgan Stanley | Buy → Hold Downgrades $17 → $12 | Buy → Hold | Downgrades | $17 → $12 | +75.82% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
643.62M
from 528.30M
Increased by 21.83%
Revenue Next Year
786.22M
from 643.62M
Increased by 22.16%
EPS This Year
0.03
from -0.18
EPS Next Year
0.34
from 0.03
Increased by 1,049.95%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 679.4M | 848.7M | 1.1B | ||
| Avg | 643.6M | 786.2M | 959.4M | ||
| Low | 600.2M | 729.2M | 827.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.6% | 31.9% | 36.6% | ||
| Avg | 21.8% | 22.2% | 22.0% | ||
| Low | 13.6% | 13.3% | 5.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.12 | 0.54 | 1.06 | ||
| Avg | 0.03 | 0.34 | 0.75 | ||
| Low | -0.02 | 0.09 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,717.2% | 213.0% | ||
| Avg | - | 1,049.9% | 122.1% | ||
| Low | - | 199.3% | 35.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.